385 related articles for article (PubMed ID: 21670768)
1. Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis.
Costa AG; Cusano NE; Silva BC; Cremers S; Bilezikian JP
Nat Rev Rheumatol; 2011 Jun; 7(8):447-56. PubMed ID: 21670768
[TBL] [Abstract][Full Text] [Related]
2. [Reducing bone resorption by cathepsin K inhibitor and treatment of osteoporosis].
Watanabe R; Okazaki R
Clin Calcium; 2014 Jan; 24(1):59-67. PubMed ID: 24369281
[TBL] [Abstract][Full Text] [Related]
3. Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis.
Stone JA; McCrea JB; Witter R; Zajic S; Stoch SA
Br J Clin Pharmacol; 2019 Jun; 85(6):1072-1083. PubMed ID: 30663085
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of cathepsin K for treatment of osteoporosis.
Boonen S; Rosenberg E; Claessens F; Vanderschueren D; Papapoulos S
Curr Osteoporos Rep; 2012 Mar; 10(1):73-9. PubMed ID: 22228398
[TBL] [Abstract][Full Text] [Related]
5. Cathepsin K Inhibition: A New Mechanism for the Treatment of Osteoporosis.
Duong le T; Leung AT; Langdahl B
Calcif Tissue Int; 2016 Apr; 98(4):381-97. PubMed ID: 26335104
[TBL] [Abstract][Full Text] [Related]
6. Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned.
Drake MT; Clarke BL; Oursler MJ; Khosla S
Endocr Rev; 2017 Aug; 38(4):325-350. PubMed ID: 28651365
[TBL] [Abstract][Full Text] [Related]
7. Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling.
Lewiecki EM
IDrugs; 2009 Dec; 12(12):799-809. PubMed ID: 19943223
[TBL] [Abstract][Full Text] [Related]
8. Cathepsin K inhibitors: a novel target but promising approach in the treatment of osteoporosis.
Helali AM; Iti FM; Mohamed IN
Curr Drug Targets; 2013 Dec; 14(13):1591-600. PubMed ID: 23957815
[TBL] [Abstract][Full Text] [Related]
9. [Odanacatib (MK-0822)].
Nagase Y; Tanaka S
Clin Calcium; 2011 Jan; 21(1):59-62. PubMed ID: 21187595
[TBL] [Abstract][Full Text] [Related]
10. Potential role of odanacatib in the treatment of osteoporosis.
Ng KW
Clin Interv Aging; 2012; 7():235-47. PubMed ID: 22866001
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological inhibition of cathepsin K: A promising novel approach for postmenopausal osteoporosis therapy.
Mukherjee K; Chattopadhyay N
Biochem Pharmacol; 2016 Oct; 117():10-9. PubMed ID: 27106079
[TBL] [Abstract][Full Text] [Related]
12. Odanacatib in postmenopausal women with low bone mineral density: a review of current clinical evidence.
Zerbini CA; McClung MR
Ther Adv Musculoskelet Dis; 2013 Aug; 5(4):199-209. PubMed ID: 23904864
[TBL] [Abstract][Full Text] [Related]
13. Cathepsin K inhibitors for osteoporosis and potential off-target effects.
Brömme D; Lecaille F
Expert Opin Investig Drugs; 2009 May; 18(5):585-600. PubMed ID: 19388876
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of cathepsin K: a patent review (2004 - 2010).
Wijkmans J; Gossen J
Expert Opin Ther Pat; 2011 Oct; 21(10):1611-29. PubMed ID: 21923554
[TBL] [Abstract][Full Text] [Related]
15. A patent review on cathepsin K inhibitors to treat osteoporosis (2011 - 2021).
Rocho FR; Bonatto V; Lameiro RF; Lameira J; Leitão A; Montanari CA
Expert Opin Ther Pat; 2022 May; 32(5):561-573. PubMed ID: 35137661
[TBL] [Abstract][Full Text] [Related]
16. A Mild Inhibition of Cathepsin K Paradoxically Stimulates the Resorptive Activity of Osteoclasts in Culture.
Pirapaharan DC; Søe K; Panwar P; Madsen JS; Bergmann ML; Overgaard M; Brömme D; Delaisse JM
Calcif Tissue Int; 2019 Jan; 104(1):92-101. PubMed ID: 30194476
[TBL] [Abstract][Full Text] [Related]
17. Advances in the discovery of cathepsin K inhibitors on bone resorption.
Lu J; Wang M; Wang Z; Fu Z; Lu A; Zhang G
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):890-904. PubMed ID: 29723068
[TBL] [Abstract][Full Text] [Related]
18. Odanacatib for the treatment of osteoporosis.
Boggild MK; Gajic-Veljanoski O; McDonald-Blumer H; Ridout R; Tile L; Josse R; Cheung AM
Expert Opin Pharmacother; 2015; 16(11):1717-26. PubMed ID: 26149759
[TBL] [Abstract][Full Text] [Related]
19. Cathepsin K osteoporosis trials, pycnodysostosis and mouse deficiency models: Commonalities and differences.
Brömme D; Panwar P; Turan S
Expert Opin Drug Discov; 2016; 11(5):457-72. PubMed ID: 27001692
[TBL] [Abstract][Full Text] [Related]
20. Odanacatib: an emerging novel treatment alternative for postmenopausal osteoporosis.
Schultz TC; Valenzano JP; Verzella JL; Umland EM
Womens Health (Lond); 2015 Nov; 11(6):805-14. PubMed ID: 26344800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]